uniQure N.V. Current Portion of Long-Term Debt
uniQure N.V. (QURE) had Current Portion of Long-Term Debt of $11.11 million as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LongTermDebtCurrent · last filed 2019-02-28
- 2018-09-30: Long-term Debt, Current Maturities $11.11M.
- 2018-06-30: Long-term Debt, Current Maturities $8.03M.
- 2018-03-31: Long-term Debt, Current Maturities $4.44M.
- 2017-12-31: Long-term Debt, Current Maturities $1.05M.
| Period end | Long-term Debt, Current Maturities |
|---|---|
| 2018-09-30 | $11.11M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $8.03M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $4.44M 10-Q · filed 2018-04-30 |
| 2017-12-31 | $1.05M 10-K · filed 2019-02-28 |
| 2017-09-30 | $6.23M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $4.32M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $2.44M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $605.00K 10-K · filed 2018-03-14 |
| 2015-12-31 | $5.58M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |